ArticleDiscover oncology2025
Identification of ITGA2 as a methylation-regulated oncogene through a CeRNA network in papillary thyroid carcinoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectivePapillary thyroid carcinoma (PTC) is the most common endocrine malignancy. This study aimed to construct a competing endogenous RNA (ceRNA) network to identify potential molecular targets and validate their biological functions.
methodsGene expression profiles from the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) databases were integrated to construct a miRNA-mediated mRNA-mRNA network within a ceRNA framework. Pathway enrichment analysis was applied to identify candidate genes. Differential expression in clinical specimens was validated by Western blot and qRT-PCR. Functional assays were performed after target gene silencing in PTC cell lines. Methylation specific PCR (MSP) was used to assess the relationship between promoter methylation and gene expression.
resultsA total of 160 potential ceRNA pairs were identified, of which 51 were associated with methylation status. Functional enrichment analysis further narrowed the candidates to eight tumorigenesis-related genes. Among these, integrin alpha 2 (ITGA2) was significantly overexpressed in PTC tissues. ITGA2 knockdown in PTC cells markedly suppressed proliferation, invasion, and metastatic capacity. MSP analysis demonstrated reduced promoter methylation of ITGA2 in PTC cells relative to controls, indicating that its upregulation is linked to promoter hypomethylation.
conclusionsThis study established a ceRNA regulatory network in PTC and identified ITGA2 as a potential therapeutic target. Its dysregulated expression is closely associated with epigenetic alterations, offering new insights into the molecular mechanisms of PTC progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.